Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
The Ras Gene02:38

The Ras Gene

7.0K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.0K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

5.2K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.2K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HDAC inhibition sensitizes pancreatic tumors to DNA damage by global redistribution of the transcriptional machinery.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Med14 phosphorylation shapes genomic response to GLP-1 agonists.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

A Legacy of Mentorship: A Tribute to Lewis Cantley.

Cancer discovery·2026
Same author

Synthesis and Characterization of ULK1/2 Kinase Inhibitors That Inhibit Autophagy and Upregulate Expression of Major Histocompatibility Complex I for the Treatment of Non-Small Cell Lung Cancer.

ACS chemical biology·2026
Same author

The Aging Microenvironment Is a Determinant of Immune Exclusion and Metastatic Fate in Pancreatic Cancer.

Cancer research·2025
Same author

Organellar pH as an emerging vulnerability to exploit in cancer.

Trends in cancer·2025

Related Experiment Video

Updated: Jan 10, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.5K

ULK1/2 Inhibitors that Degrade ATG13 Effectively Target KRAS-Mutant Cancers.

Patrick M Hagan, Huiyu Ren, Sonja N Brun

    Biorxiv : the Preprint Server for Biology
    |November 24, 2025
    PubMed
    Summary

    A novel drug, SBP-1750, targets autophagy-related gene (ATG) proteins in KRAS-mutant cancers. This drug inhibits ULK1 kinase activity, degrades key ATG proteins, and reduces tumor growth, offering a new therapeutic strategy.

    More Related Videos

    Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
    08:12

    Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

    Published on: October 5, 2020

    3.3K
    Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
    09:29

    Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

    Published on: September 30, 2016

    14.3K

    Related Experiment Videos

    Last Updated: Jan 10, 2026

    Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
    06:51

    Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

    Published on: July 21, 2018

    18.5K
    Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
    08:12

    Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

    Published on: October 5, 2020

    3.3K
    Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
    09:29

    Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

    Published on: September 30, 2016

    14.3K

    Area of Science:

    • Oncology
    • Molecular Biology
    • Cancer Therapeutics

    Background:

    • KRAS mutations are key drivers in lung and pancreatic cancers.
    • Autophagy, initiated by ULK kinases, supports tumor growth and is a target for KRAS-mutant cancers.
    • ULK1 and ATG13 are essential components of the autophagy initiation complex.

    Purpose of the Study:

    • To identify and evaluate ULK inhibitors targeting autophagy in KRAS-mutant cancers.
    • To assess the efficacy of a novel ULK inhibitor, SBP-1750, in preclinical cancer models.

    Main Methods:

    • Developed a high-throughput screening assay using HiBiT-tagged ATG13 in KRAS-mutant lung cancer cells.
    • Tested SBP-1750 for ULK kinase inhibition and ATG13 degradation.
    • Evaluated SBP-1750's anti-tumor efficacy in an orthotopic pancreatic cancer model and analyzed immune cell infiltration.

    Main Results:

    • SBP-1750 potently inhibited ULK activity and induced ATG13 degradation, leading to KRAS-mutant cancer cell death.
    • Oral administration of SBP-1750 significantly reduced tumor growth in a pancreatic cancer model.
    • SBP-1750 treatment increased CD4+ and CD8+ T cell infiltration in tumors, enhancing anti-tumor immunity.

    Conclusions:

    • SBP-1750 is a promising novel therapeutic agent targeting the autophagy pathway in KRAS-mutant cancers.
    • SBP-1750 demonstrates anti-tumor activity and immunomodulatory effects.
    • Further development of SBP-1750 as an ATG-targeting cancer therapy is warranted.